Research at the Faculty of Pharmacy is structured around themes that closely reflect the Australian government’s health priorities: cancer, cardiovascular disease and diabetes, healthy ageing, mental health and respiratory disease.
The research covers a broad spectrum of pharmaceutical and clinical sciences, including:
- the design, synthesis, testing and mechanism of action of drugs
- studies on advanced drug delivery
- investigation of the fate of drugs in humans including pharmacogenomics and other aspects of drug disposition, and
- research on the clinical and sociological aspects of pharmacy and health services research.
Cancer is a major health issue in Australia today. At current rates, the Cancer Council of Australia expects that by the age of 85 one in two men and one in three women will be diagnosed with cancer. Research projects include personalised anti-cancer therapy, drug resistance, the use of herbal medicines and design of new therapies.
Australians are getting older, heavier and less active, putting themselves at greater risk of cardiovascular disease (CVD) and diabetes. CVD is the number one cause of death in Australia, according to the Heart Foundation, and diabetes is the country’s fastest growing chronic disease and the sixth leading cause of death. Faculty research covers a range of cardiovascular diseases and problems from atherosclerosis and thromboembolism to cardiac infarction and stroke.
Health services and patient safety research in the Faculty of Pharmacy focuses on research that informs health policy and influences practice. This theme takes a system-wide view to ensure that research and innovation is able to improve health outcomes for consumers and improve the safety and effectiveness of the health system.
With more than 2 million people having asthma, Australia has one of the largest populations of asthma patients in the world. Research into respiratory diseases in the faculty has yielded crucial findings for improving asthma treatment alongside other respiratory conditions such as cystic fibrosis and chronic obstructive pulmonary disease (COPD).